nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ABCB1—esophageal cancer	0.535	1	CbGaD
Propranolol—SLC22A2—Cisplatin—esophageal cancer	0.0588	0.695	CbGbCtD
Propranolol—ABCB1—Cisplatin—esophageal cancer	0.0157	0.185	CbGbCtD
Propranolol—ABCB1—Methotrexate—esophageal cancer	0.0102	0.12	CbGbCtD
Propranolol—Methocarbamol—CA1—esophageal cancer	0.00611	0.415	CrCbGaD
Propranolol—Lower respiratory tract infection—Capecitabine—esophageal cancer	0.00368	0.0377	CcSEcCtD
Propranolol—Arterial thrombosis—Methotrexate—esophageal cancer	0.00347	0.0356	CcSEcCtD
Propranolol—Carvedilol—HIF1A—esophageal cancer	0.00294	0.199	CrCbGaD
Propranolol—Peripheral coldness—Capecitabine—esophageal cancer	0.00264	0.027	CcSEcCtD
Propranolol—Infection—Carboplatin—esophageal cancer	0.00206	0.0211	CcSEcCtD
Propranolol—Respiratory distress—Capecitabine—esophageal cancer	0.00198	0.0203	CcSEcCtD
Propranolol—Pain—Carboplatin—esophageal cancer	0.00177	0.0182	CcSEcCtD
Propranolol—Throat sore—Capecitabine—esophageal cancer	0.00174	0.0179	CcSEcCtD
Propranolol—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00173	0.0177	CcSEcCtD
Propranolol—Hyperkalaemia—Cisplatin—esophageal cancer	0.00168	0.0172	CcSEcCtD
Propranolol—Rash erythematous—Capecitabine—esophageal cancer	0.00164	0.0168	CcSEcCtD
Propranolol—Body temperature increased—Carboplatin—esophageal cancer	0.00164	0.0168	CcSEcCtD
Propranolol—Skin ulcer—Capecitabine—esophageal cancer	0.00161	0.0165	CcSEcCtD
Propranolol—Terbinafine—CYP19A1—esophageal cancer	0.00157	0.107	CrCbGaD
Propranolol—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00138	0.0142	CcSEcCtD
Propranolol—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00137	0.014	CcSEcCtD
Propranolol—Amnesia—Cisplatin—esophageal cancer	0.00132	0.0135	CcSEcCtD
Propranolol—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00128	0.0131	CcSEcCtD
Propranolol—Terbinafine—PTGS1—esophageal cancer	0.00127	0.0859	CrCbGaD
Propranolol—Skin ulcer—Methotrexate—esophageal cancer	0.0012	0.0123	CcSEcCtD
Propranolol—Irritability—Cisplatin—esophageal cancer	0.00118	0.0121	CcSEcCtD
Propranolol—Dry eye—Capecitabine—esophageal cancer	0.00116	0.0119	CcSEcCtD
Propranolol—Sleep disorder—Capecitabine—esophageal cancer	0.00105	0.0108	CcSEcCtD
Propranolol—Vascular purpura—Capecitabine—esophageal cancer	0.00102	0.0104	CcSEcCtD
Propranolol—Amnesia—Capecitabine—esophageal cancer	0.000971	0.00994	CcSEcCtD
Propranolol—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000967	0.0099	CcSEcCtD
Propranolol—Purpura—Capecitabine—esophageal cancer	0.000947	0.00969	CcSEcCtD
Propranolol—Lethargy—Capecitabine—esophageal cancer	0.000931	0.00953	CcSEcCtD
Propranolol—Bradycardia—Cisplatin—esophageal cancer	0.000872	0.00892	CcSEcCtD
Propranolol—Irritability—Capecitabine—esophageal cancer	0.000871	0.00892	CcSEcCtD
Propranolol—Cardiac arrest—Capecitabine—esophageal cancer	0.000868	0.00888	CcSEcCtD
Propranolol—Mood swings—Capecitabine—esophageal cancer	0.000864	0.00885	CcSEcCtD
Propranolol—Visual impairment—Cisplatin—esophageal cancer	0.000825	0.00845	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000822	0.00841	CcSEcCtD
Propranolol—Cardiac disorder—Cisplatin—esophageal cancer	0.000795	0.00814	CcSEcCtD
Propranolol—Bronchospasm—Capecitabine—esophageal cancer	0.000776	0.00794	CcSEcCtD
Propranolol—Bronchitis—Capecitabine—esophageal cancer	0.000759	0.00776	CcSEcCtD
Propranolol—Alopecia—Cisplatin—esophageal cancer	0.000757	0.00775	CcSEcCtD
Propranolol—Erythema—Cisplatin—esophageal cancer	0.000746	0.00763	CcSEcCtD
Propranolol—Neutropenia—Capecitabine—esophageal cancer	0.000738	0.00755	CcSEcCtD
Propranolol—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00072	0.00737	CcSEcCtD
Propranolol—Visual disturbance—Methotrexate—esophageal cancer	0.000717	0.00734	CcSEcCtD
Propranolol—Infestation NOS—Capecitabine—esophageal cancer	0.000703	0.0072	CcSEcCtD
Propranolol—Infestation—Capecitabine—esophageal cancer	0.000703	0.0072	CcSEcCtD
Propranolol—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000702	0.00718	CcSEcCtD
Propranolol—Depression—Capecitabine—esophageal cancer	0.000701	0.00718	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000697	0.00714	CcSEcCtD
Propranolol—Lethargy—Methotrexate—esophageal cancer	0.000693	0.0071	CcSEcCtD
Propranolol—Agranulocytosis—Capecitabine—esophageal cancer	0.000656	0.00672	CcSEcCtD
Propranolol—Irritability—Methotrexate—esophageal cancer	0.000648	0.00664	CcSEcCtD
Propranolol—Convulsion—Cisplatin—esophageal cancer	0.000646	0.00661	CcSEcCtD
Propranolol—Mood swings—Methotrexate—esophageal cancer	0.000644	0.00659	CcSEcCtD
Propranolol—Bradycardia—Capecitabine—esophageal cancer	0.000643	0.00658	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00063	0.00645	CcSEcCtD
Propranolol—Pharyngitis—Capecitabine—esophageal cancer	0.000627	0.00641	CcSEcCtD
Propranolol—Carvedilol—PTGS1—esophageal cancer	0.000625	0.0424	CrCbGaD
Propranolol—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000612	0.00626	CcSEcCtD
Propranolol—Anaphylactic shock—Cisplatin—esophageal cancer	0.000608	0.00623	CcSEcCtD
Propranolol—Visual impairment—Capecitabine—esophageal cancer	0.000608	0.00623	CcSEcCtD
Propranolol—Infection—Cisplatin—esophageal cancer	0.000604	0.00619	CcSEcCtD
Propranolol—Erythema multiforme—Capecitabine—esophageal cancer	0.000597	0.00611	CcSEcCtD
Propranolol—Nervous system disorder—Cisplatin—esophageal cancer	0.000597	0.00611	CcSEcCtD
Propranolol—Skin disorder—Cisplatin—esophageal cancer	0.000591	0.00605	CcSEcCtD
Propranolol—Atenolol—ABCB1—esophageal cancer	0.000587	0.0398	CrCbGaD
Propranolol—Cardiac disorder—Capecitabine—esophageal cancer	0.000586	0.006	CcSEcCtD
Propranolol—Alopecia—Capecitabine—esophageal cancer	0.000558	0.00571	CcSEcCtD
Propranolol—Mental disorder—Capecitabine—esophageal cancer	0.000553	0.00566	CcSEcCtD
Propranolol—Erythema—Capecitabine—esophageal cancer	0.00055	0.00563	CcSEcCtD
Propranolol—Neutropenia—Methotrexate—esophageal cancer	0.000549	0.00562	CcSEcCtD
Propranolol—Paraesthesia—Cisplatin—esophageal cancer	0.000546	0.00559	CcSEcCtD
Propranolol—Dyspnoea—Cisplatin—esophageal cancer	0.000542	0.00555	CcSEcCtD
Propranolol—Acebutolol—ABCB1—esophageal cancer	0.000542	0.0368	CrCbGaD
Propranolol—Erectile dysfunction—Methotrexate—esophageal cancer	0.000541	0.00554	CcSEcCtD
Propranolol—Decreased appetite—Cisplatin—esophageal cancer	0.000529	0.00541	CcSEcCtD
Propranolol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000525	0.00538	CcSEcCtD
Propranolol—Infestation NOS—Methotrexate—esophageal cancer	0.000523	0.00536	CcSEcCtD
Propranolol—Infestation—Methotrexate—esophageal cancer	0.000523	0.00536	CcSEcCtD
Propranolol—Depression—Methotrexate—esophageal cancer	0.000522	0.00534	CcSEcCtD
Propranolol—Pain—Cisplatin—esophageal cancer	0.00052	0.00533	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000519	0.00531	CcSEcCtD
Propranolol—Vertigo—Capecitabine—esophageal cancer	0.000494	0.00505	CcSEcCtD
Propranolol—Agranulocytosis—Methotrexate—esophageal cancer	0.000489	0.005	CcSEcCtD
Propranolol—Body temperature increased—Cisplatin—esophageal cancer	0.000481	0.00492	CcSEcCtD
Propranolol—Cough—Capecitabine—esophageal cancer	0.00048	0.00491	CcSEcCtD
Propranolol—Pharyngitis—Methotrexate—esophageal cancer	0.000466	0.00477	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000465	0.00476	CcSEcCtD
Propranolol—Metoprolol—ABCB1—esophageal cancer	0.000458	0.031	CrCbGaD
Propranolol—Visual impairment—Methotrexate—esophageal cancer	0.000453	0.00464	CcSEcCtD
Propranolol—Hypersensitivity—Cisplatin—esophageal cancer	0.000448	0.00459	CcSEcCtD
Propranolol—Infection—Capecitabine—esophageal cancer	0.000446	0.00456	CcSEcCtD
Propranolol—Erythema multiforme—Methotrexate—esophageal cancer	0.000444	0.00455	CcSEcCtD
Propranolol—Nervous system disorder—Capecitabine—esophageal cancer	0.00044	0.0045	CcSEcCtD
Propranolol—Asthenia—Cisplatin—esophageal cancer	0.000437	0.00447	CcSEcCtD
Propranolol—Cardiac disorder—Methotrexate—esophageal cancer	0.000436	0.00446	CcSEcCtD
Propranolol—Skin disorder—Capecitabine—esophageal cancer	0.000436	0.00446	CcSEcCtD
Propranolol—Diarrhoea—Cisplatin—esophageal cancer	0.000416	0.00426	CcSEcCtD
Propranolol—Alopecia—Methotrexate—esophageal cancer	0.000415	0.00425	CcSEcCtD
Propranolol—Mental disorder—Methotrexate—esophageal cancer	0.000412	0.00421	CcSEcCtD
Propranolol—Erythema—Methotrexate—esophageal cancer	0.000409	0.00419	CcSEcCtD
Propranolol—Insomnia—Capecitabine—esophageal cancer	0.000406	0.00415	CcSEcCtD
Propranolol—Paraesthesia—Capecitabine—esophageal cancer	0.000403	0.00412	CcSEcCtD
Propranolol—Dyspnoea—Capecitabine—esophageal cancer	0.0004	0.00409	CcSEcCtD
Propranolol—Dyspepsia—Capecitabine—esophageal cancer	0.000395	0.00404	CcSEcCtD
Propranolol—Decreased appetite—Capecitabine—esophageal cancer	0.00039	0.00399	CcSEcCtD
Propranolol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000387	0.00396	CcSEcCtD
Propranolol—Vomiting—Cisplatin—esophageal cancer	0.000387	0.00396	CcSEcCtD
Propranolol—Fatigue—Capecitabine—esophageal cancer	0.000387	0.00396	CcSEcCtD
Propranolol—Rash—Cisplatin—esophageal cancer	0.000384	0.00393	CcSEcCtD
Propranolol—Pain—Capecitabine—esophageal cancer	0.000384	0.00393	CcSEcCtD
Propranolol—Constipation—Capecitabine—esophageal cancer	0.000384	0.00393	CcSEcCtD
Propranolol—Dermatitis—Cisplatin—esophageal cancer	0.000383	0.00392	CcSEcCtD
Propranolol—Vertigo—Methotrexate—esophageal cancer	0.000368	0.00376	CcSEcCtD
Propranolol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000367	0.00375	CcSEcCtD
Propranolol—Nausea—Cisplatin—esophageal cancer	0.000361	0.0037	CcSEcCtD
Propranolol—Cough—Methotrexate—esophageal cancer	0.000357	0.00365	CcSEcCtD
Propranolol—Urticaria—Capecitabine—esophageal cancer	0.000356	0.00365	CcSEcCtD
Propranolol—Abdominal pain—Capecitabine—esophageal cancer	0.000355	0.00363	CcSEcCtD
Propranolol—Body temperature increased—Capecitabine—esophageal cancer	0.000355	0.00363	CcSEcCtD
Propranolol—Convulsion—Methotrexate—esophageal cancer	0.000354	0.00363	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000346	0.00354	CcSEcCtD
Propranolol—Propafenone—ABCB1—esophageal cancer	0.000337	0.0229	CrCbGaD
Propranolol—Anaphylactic shock—Methotrexate—esophageal cancer	0.000334	0.00342	CcSEcCtD
Propranolol—Infection—Methotrexate—esophageal cancer	0.000332	0.0034	CcSEcCtD
Propranolol—Hypersensitivity—Capecitabine—esophageal cancer	0.00033	0.00338	CcSEcCtD
Propranolol—Nervous system disorder—Methotrexate—esophageal cancer	0.000327	0.00335	CcSEcCtD
Propranolol—Skin disorder—Methotrexate—esophageal cancer	0.000324	0.00332	CcSEcCtD
Propranolol—Asthenia—Capecitabine—esophageal cancer	0.000322	0.00329	CcSEcCtD
Propranolol—Diarrhoea—Capecitabine—esophageal cancer	0.000307	0.00314	CcSEcCtD
Propranolol—Carvedilol—ABCB1—esophageal cancer	0.000304	0.0206	CrCbGaD
Propranolol—Insomnia—Methotrexate—esophageal cancer	0.000302	0.00309	CcSEcCtD
Propranolol—Paraesthesia—Methotrexate—esophageal cancer	0.0003	0.00307	CcSEcCtD
Propranolol—Dyspnoea—Methotrexate—esophageal cancer	0.000298	0.00305	CcSEcCtD
Propranolol—Somnolence—Methotrexate—esophageal cancer	0.000297	0.00304	CcSEcCtD
Propranolol—Dizziness—Capecitabine—esophageal cancer	0.000297	0.00304	CcSEcCtD
Propranolol—Dyspepsia—Methotrexate—esophageal cancer	0.000294	0.00301	CcSEcCtD
Propranolol—Decreased appetite—Methotrexate—esophageal cancer	0.00029	0.00297	CcSEcCtD
Propranolol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000288	0.00295	CcSEcCtD
Propranolol—Fatigue—Methotrexate—esophageal cancer	0.000288	0.00295	CcSEcCtD
Propranolol—Pain—Methotrexate—esophageal cancer	0.000286	0.00292	CcSEcCtD
Propranolol—Vomiting—Capecitabine—esophageal cancer	0.000285	0.00292	CcSEcCtD
Propranolol—Rash—Capecitabine—esophageal cancer	0.000283	0.00289	CcSEcCtD
Propranolol—Dermatitis—Capecitabine—esophageal cancer	0.000283	0.00289	CcSEcCtD
Propranolol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000273	0.00279	CcSEcCtD
Propranolol—Nausea—Capecitabine—esophageal cancer	0.000266	0.00273	CcSEcCtD
Propranolol—Urticaria—Methotrexate—esophageal cancer	0.000265	0.00272	CcSEcCtD
Propranolol—Body temperature increased—Methotrexate—esophageal cancer	0.000264	0.0027	CcSEcCtD
Propranolol—Abdominal pain—Methotrexate—esophageal cancer	0.000264	0.0027	CcSEcCtD
Propranolol—Hypersensitivity—Methotrexate—esophageal cancer	0.000246	0.00252	CcSEcCtD
Propranolol—Asthenia—Methotrexate—esophageal cancer	0.00024	0.00245	CcSEcCtD
Propranolol—Diarrhoea—Methotrexate—esophageal cancer	0.000228	0.00234	CcSEcCtD
Propranolol—Dizziness—Methotrexate—esophageal cancer	0.000221	0.00226	CcSEcCtD
Propranolol—Vomiting—Methotrexate—esophageal cancer	0.000212	0.00217	CcSEcCtD
Propranolol—Rash—Methotrexate—esophageal cancer	0.000211	0.00215	CcSEcCtD
Propranolol—Dermatitis—Methotrexate—esophageal cancer	0.00021	0.00215	CcSEcCtD
Propranolol—Nausea—Methotrexate—esophageal cancer	0.000198	0.00203	CcSEcCtD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.53e-05	0.000131	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	3.52e-05	0.000131	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PSME1—esophageal cancer	3.5e-05	0.00013	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PSME2—esophageal cancer	3.5e-05	0.00013	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GAPDH—esophageal cancer	3.49e-05	0.00013	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTO1—esophageal cancer	3.48e-05	0.00013	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—TPI1—esophageal cancer	3.48e-05	0.00013	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CRABP1—esophageal cancer	3.46e-05	0.000129	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—ABCB1—esophageal cancer	3.44e-05	0.000128	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	3.44e-05	0.000128	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—ABCB1—esophageal cancer	3.43e-05	0.000128	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ADH1B—esophageal cancer	3.41e-05	0.000127	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GAPDH—esophageal cancer	3.4e-05	0.000127	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CREBBP—esophageal cancer	3.4e-05	0.000127	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.4e-05	0.000127	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CRABP1—esophageal cancer	3.37e-05	0.000126	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS1—esophageal cancer	3.35e-05	0.000125	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ENO1—esophageal cancer	3.35e-05	0.000125	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—EGFR—esophageal cancer	3.34e-05	0.000125	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ALDOB—esophageal cancer	3.33e-05	0.000124	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PSME2—esophageal cancer	3.31e-05	0.000123	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PSME1—esophageal cancer	3.31e-05	0.000123	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GNG7—esophageal cancer	3.29e-05	0.000123	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.29e-05	0.000123	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—TYMP—esophageal cancer	3.26e-05	0.000121	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CA2—esophageal cancer	3.22e-05	0.00012	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GNG7—esophageal cancer	3.21e-05	0.00012	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GAPDH—esophageal cancer	3.21e-05	0.00012	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—PIK3CA—esophageal cancer	3.19e-05	0.000119	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	3.19e-05	0.000119	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CRABP1—esophageal cancer	3.18e-05	0.000119	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP26A1—esophageal cancer	3.17e-05	0.000118	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	3.12e-05	0.000116	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HIF1A—esophageal cancer	3.1e-05	0.000116	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ALOX15—esophageal cancer	3.09e-05	0.000115	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ALDH2—esophageal cancer	3.08e-05	0.000115	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	3.05e-05	0.000114	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—NOS3—esophageal cancer	3.04e-05	0.000113	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GNG7—esophageal cancer	3.02e-05	0.000113	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP1B1—esophageal cancer	3.02e-05	0.000113	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	3.02e-05	0.000113	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ALDH2—esophageal cancer	3.01e-05	0.000112	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ADH7—esophageal cancer	3e-05	0.000112	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PLCE1—esophageal cancer	3e-05	0.000112	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KDR—esophageal cancer	2.97e-05	0.000111	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	2.95e-05	0.00011	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—TPI1—esophageal cancer	2.94e-05	0.00011	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTO1—esophageal cancer	2.94e-05	0.00011	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GSTT1—esophageal cancer	2.93e-05	0.000109	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—PIK3CA—esophageal cancer	2.9e-05	0.000108	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.9e-05	0.000108	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.89e-05	0.000108	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	2.89e-05	0.000108	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.88e-05	0.000108	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GSTT1—esophageal cancer	2.86e-05	0.000107	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP1B1—esophageal cancer	2.85e-05	0.000106	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—ERBB2—esophageal cancer	2.85e-05	0.000106	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP19A1—esophageal cancer	2.84e-05	0.000106	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.83e-05	0.000106	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.83e-05	0.000105	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ALDOB—esophageal cancer	2.82e-05	0.000105	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NOTCH1—esophageal cancer	2.79e-05	0.000104	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ENO1—esophageal cancer	2.75e-05	0.000102	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS1—esophageal cancer	2.75e-05	0.000102	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GAPDH—esophageal cancer	2.72e-05	0.000101	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PSME2—esophageal cancer	2.71e-05	0.000101	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PSME1—esophageal cancer	2.71e-05	0.000101	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.69e-05	0.0001	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CRABP1—esophageal cancer	2.69e-05	0.0001	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP19A1—esophageal cancer	2.68e-05	0.0001	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ENO1—esophageal cancer	2.68e-05	9.99e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS1—esophageal cancer	2.68e-05	9.99e-05	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.68e-05	9.98e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.66e-05	9.93e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PSME2—esophageal cancer	2.64e-05	9.84e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PSME1—esophageal cancer	2.64e-05	9.84e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.63e-05	9.8e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—HMOX1—esophageal cancer	2.59e-05	9.66e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GNG7—esophageal cancer	2.56e-05	9.55e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	2.53e-05	9.44e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ENO1—esophageal cancer	2.52e-05	9.41e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.52e-05	9.41e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCND1—esophageal cancer	2.51e-05	9.37e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—TYMP—esophageal cancer	2.51e-05	9.37e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	2.49e-05	9.28e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PSME2—esophageal cancer	2.49e-05	9.28e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PSME1—esophageal cancer	2.49e-05	9.28e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—ABCB1—esophageal cancer	2.49e-05	9.27e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	2.47e-05	9.21e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—HMOX1—esophageal cancer	2.45e-05	9.13e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.44e-05	9.11e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CDKN1A—esophageal cancer	2.43e-05	9.07e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	2.42e-05	9.01e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.4e-05	8.95e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ALDH2—esophageal cancer	2.4e-05	8.95e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.38e-05	8.88e-05	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.38e-05	8.87e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.36e-05	8.81e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	2.36e-05	8.81e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KDR—esophageal cancer	2.36e-05	8.8e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ABCB1—esophageal cancer	2.35e-05	8.76e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP1B1—esophageal cancer	2.33e-05	8.7e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—EP300—esophageal cancer	2.31e-05	8.63e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KDR—esophageal cancer	2.31e-05	8.61e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—CREBBP—esophageal cancer	2.3e-05	8.57e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—CREBBP—esophageal cancer	2.3e-05	8.56e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTT1—esophageal cancer	2.28e-05	8.51e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.28e-05	8.5e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.27e-05	8.47e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—TPI1—esophageal cancer	2.27e-05	8.47e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NOS3—esophageal cancer	2.27e-05	8.45e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KDR—esophageal cancer	2.26e-05	8.42e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP2A6—esophageal cancer	2.26e-05	8.41e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.25e-05	8.38e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	2.22e-05	8.29e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP19A1—esophageal cancer	2.19e-05	8.18e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.18e-05	8.12e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	2.18e-05	8.11e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	2.16e-05	8.05e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.15e-05	8.01e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.14e-05	7.99e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.14e-05	7.98e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ENO1—esophageal cancer	2.14e-05	7.98e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	2.13e-05	7.93e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	2.12e-05	7.91e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PSME1—esophageal cancer	2.11e-05	7.86e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PSME2—esophageal cancer	2.11e-05	7.86e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.1e-05	7.82e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.08e-05	7.75e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—NOS3—esophageal cancer	2.06e-05	7.67e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—NOS3—esophageal cancer	2.05e-05	7.66e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.02e-05	7.53e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	2.02e-05	7.52e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MYC—esophageal cancer	2.02e-05	7.52e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—HMOX1—esophageal cancer	2e-05	7.47e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	1.98e-05	7.39e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GNG7—esophageal cancer	1.98e-05	7.37e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	1.97e-05	7.36e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—EGFR—esophageal cancer	1.97e-05	7.35e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.96e-05	7.33e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—HMOX1—esophageal cancer	1.95e-05	7.29e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	1.94e-05	7.23e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	1.93e-05	7.19e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.92e-05	7.17e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	1.9e-05	7.07e-05	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.89e-05	7.06e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.88e-05	7.02e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTGS2—esophageal cancer	1.88e-05	7.01e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCND1—esophageal cancer	1.87e-05	6.99e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.85e-05	6.91e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.85e-05	6.91e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.84e-05	6.87e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.84e-05	6.86e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.82e-05	6.78e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	1.81e-05	6.76e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.81e-05	6.76e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	1.81e-05	6.73e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.78e-05	6.62e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.77e-05	6.59e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	1.77e-05	6.59e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.76e-05	6.57e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.74e-05	6.49e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.73e-05	6.44e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EP300—esophageal cancer	1.72e-05	6.43e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	1.72e-05	6.41e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PIK3CA—esophageal cancer	1.71e-05	6.38e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.71e-05	6.38e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	1.69e-05	6.3e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	1.68e-05	6.27e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.66e-05	6.2e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—esophageal cancer	1.66e-05	6.18e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	1.65e-05	6.16e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.65e-05	6.16e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ENO1—esophageal cancer	1.65e-05	6.16e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.65e-05	6.13e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PSME1—esophageal cancer	1.63e-05	6.07e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PSME2—esophageal cancer	1.63e-05	6.07e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	1.62e-05	6.02e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CREBBP—esophageal cancer	1.57e-05	5.85e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—EP300—esophageal cancer	1.57e-05	5.84e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—EP300—esophageal cancer	1.56e-05	5.83e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.56e-05	5.82e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.53e-05	5.71e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MYC—esophageal cancer	1.5e-05	5.6e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.5e-05	5.58e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	1.49e-05	5.56e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—NOS3—esophageal cancer	1.49e-05	5.55e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EGFR—esophageal cancer	1.47e-05	5.48e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	1.46e-05	5.44e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.45e-05	5.42e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	1.44e-05	5.38e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.43e-05	5.32e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	1.41e-05	5.27e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—NOS3—esophageal cancer	1.41e-05	5.24e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.4e-05	5.23e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	1.38e-05	5.15e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EP300—esophageal cancer	1.37e-05	5.12e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.36e-05	5.07e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EP300—esophageal cancer	1.34e-05	5.01e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.32e-05	4.92e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EP300—esophageal cancer	1.31e-05	4.9e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS2—esophageal cancer	1.29e-05	4.79e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.28e-05	4.79e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	1.28e-05	4.76e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CREBBP—esophageal cancer	1.25e-05	4.68e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—esophageal cancer	1.23e-05	4.6e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.2e-05	4.49e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MYC—esophageal cancer	1.2e-05	4.46e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.18e-05	4.41e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MYC—esophageal cancer	1.17e-05	4.37e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	1.17e-05	4.37e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CA—esophageal cancer	1.16e-05	4.32e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CA—esophageal cancer	1.16e-05	4.31e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.16e-05	4.31e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—NOS3—esophageal cancer	1.15e-05	4.29e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	1.15e-05	4.27e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MYC—esophageal cancer	1.14e-05	4.27e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.13e-05	4.22e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—EP300—esophageal cancer	1.13e-05	4.22e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NOS3—esophageal cancer	1.12e-05	4.19e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EGFR—esophageal cancer	1.12e-05	4.18e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—EP300—esophageal cancer	1.07e-05	3.99e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NOS3—esophageal cancer	1.06e-05	3.94e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.05e-05	3.92e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS2—esophageal cancer	1.03e-05	3.83e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	1.02e-05	3.79e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CREBBP—esophageal cancer	1e-05	3.73e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	9.94e-06	3.71e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—esophageal cancer	9.83e-06	3.67e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	9.72e-06	3.62e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS2—esophageal cancer	9.68e-06	3.61e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—esophageal cancer	9.62e-06	3.59e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—esophageal cancer	9.4e-06	3.51e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NOS3—esophageal cancer	8.96e-06	3.34e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—EP300—esophageal cancer	8.75e-06	3.26e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—EP300—esophageal cancer	8.54e-06	3.18e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CA—esophageal cancer	8.37e-06	3.12e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS2—esophageal cancer	8.2e-06	3.06e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—EP300—esophageal cancer	8.05e-06	3e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CA—esophageal cancer	7.91e-06	2.95e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CREBBP—esophageal cancer	7.73e-06	2.88e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NOS3—esophageal cancer	6.92e-06	2.58e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—EP300—esophageal cancer	6.82e-06	2.54e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CA—esophageal cancer	6.47e-06	2.41e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.33e-06	2.36e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.32e-06	2.36e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	5.95e-06	2.22e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—EP300—esophageal cancer	5.26e-06	1.96e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CA—esophageal cancer	5.04e-06	1.88e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CA—esophageal cancer	3.89e-06	1.45e-05	CbGpPWpGaD
